Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: small cellor equalequal tocell lungstage
  Phrases that lowered it: 20aminotransferaseaspartateseveredrugs
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 8.7% (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Minimum age: not given (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 94.8% (raises risk) · Drug's FDA history
• Sponsor's past trials: 195 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 66 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 24.7% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC NCT02275806 · started 2014 · scored riskier than 99% of active trials terminated
• Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer NCT01266512 · started 2011 · scored riskier than 57% of active trials completed
• Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer NCT02323737 · started 2010 · scored riskier than 50% of active trials completed
• Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) NCT01108666 · started 2010 · scored riskier than 99% of active trials terminated
• Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery NCT03132532 · started 2017 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.